

## PHARMACY / MEDICAL POLICY – 5.01.610

# Pharmacologic Treatment in Assisted Reproduction

Effective Date: Dec. 1, 2023

Last Revised: Nov. 20, 2023


Replaces: N/A

RELATED MEDICAL POLICIES:

4.02.503 Infertility and Reproductive Services

Select a hyperlink below to be directed to that section.

[POLICY CRITERIA](#) | [DOCUMENTATION REQUIREMENTS](#) | [CODING](#)  
[RELATED INFORMATION](#) | [EVIDENCE REVIEW](#) | [REFERENCES](#) | [HISTORY](#)

 Clicking this icon returns you to the hyperlinks menu above.

## Introduction

Assisted reproduction supports problems with the reproductive system that affects the ability to conceive. Different types of reproductive problems affect men and women, but the end result is the inability to conceive or complete a pregnancy. There are many reasons for infertility and drug options vary depending on the cause of infertility and type of infertility treatment required. Even though drug treatment exists, it does not mean it is covered; the member’s contract determines this. This policy describes when drugs used in assisted reproduction may be considered medically necessary if covered by the member’s contract.

**Note:** The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

## Policy Coverage Criteria

### Drug

### Medical Necessity

### Chorionic Gonadotropins

Drug	Medical Necessity
<p><b>Brand Chorionic Gonadotropin, IM</b></p> <p><b>Managed under Pharmacy and Medical benefit</b></p>	<p><b>Brand Chorionic Gonadotropin may be considered medically necessary for use in assisted reproduction when the following criteria are met:</b></p> <ul style="list-style-type: none"> <li>The individual has tried and failed or had intolerance to use of Novarel (chorionic gonadotropin) or Ovidrel (choriogonadotropin alfa)</li> </ul> <p><b>Note:</b> This policy does not apply to the use of chorionic gonadotropin for the treatment of non-assisted reproduction related conditions including but not limited to prepubertal cryptorchidism and hypogonadotropic hypogonadism.</p>
<p><b>Pregnyl (chorionic gonadotropin), IM</b></p> <p><b>Managed under Pharmacy and Medical benefit</b></p>	<p><b>Pregnyl (chorionic gonadotropin) may be considered medically necessary for use in assisted reproduction when the following criteria are met:</b></p> <ul style="list-style-type: none"> <li>The individual has tried and failed or had intolerance to use of Novarel (chorionic gonadotropin) or Ovidrel (choriogonadotropin alfa)</li> </ul> <p><b>Note:</b> This policy does not apply to the use of chorionic gonadotropin for the treatment of non-assisted reproduction related conditions including but not limited to prepubertal cryptorchidism and hypogonadotropic hypogonadism.</p>
<b>Follitropins</b>	
<p><b>Follistim AQ (follitropin beta), SC</b></p> <p><b>Managed under Pharmacy and Medical benefit</b></p>	<p><b>Follistim AQ (follitropin beta) may be considered medically necessary for use in assisted reproduction when the following criteria are met:</b></p> <ul style="list-style-type: none"> <li>The individual has tried and failed or had intolerance to use of Gonal-f (follitropin alfa) or Gonal-f RFF (follitropin alfa)</li> </ul> <p><b>Note:</b> This policy does not apply to the use of Follistim AQ (follitropin beta) for the treatment of non-assisted reproduction related conditions.</p>

Drug	Not Medically Necessary
<p><b>As listed</b></p>	<p><b>All other uses of the drugs listed for assisted reproduction are considered not medically necessary.</b></p> <p><b>Note:</b> This policy does not apply to the use of drugs listed for the treatment of non-assisted reproduction related conditions.</p>



Length of Approval	
Approval	Criteria
Initial authorization	All drugs listed in policy may be approved up to 12 months.
Re-authorization criteria	Future re-authorization of all drugs listed in policy may be approved up to 12 months as long as the drug-specific coverage criteria are met.

**Documentation Requirements**

The individual's medical records submitted for review for all conditions should document that medical necessity criteria are met. The record should include the following:

- Office visit notes that contain the diagnosis and medication history

## Coding

Code	Description
<b>HCPCS</b>	
J0725	Injection, chorionic gonadotropin, per 1,000 USP units
S0128	Injection, follitropin beta, 75 IU

**Note:** CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

## Related Information

**Note: Many benefit plans exclude assisted reproduction. Please refer to the applicable benefit plan to determine benefit availability and the terms, conditions, and limitations of coverage.**



## Benefit Application

### Pharmacy / Medical Benefit

Brand Chorionic Gonadotropin, Follistim AQ (follitropin beta), and Pregnyl (chorionic gonadotropin) are managed through both the Pharmacy and Medical benefit.

## Evidence Review

### Background

Infertility is defined as the inability to conceive after  $\geq 1$  year of unprotected intercourse. A total of 6.7% of women ages 15-44 years in the US are infertile and 12.1% have impaired fecundity, defined as difficulty getting pregnant or carrying a pregnancy to term. Assisted reproduction services have been used by 7.3 million US women or 12% of women ages 15-44 years.

Infertility has a number of different causes including combined factors (40%), male factors (26%-30%), unexplained causes (28%), ovulatory dysfunction (21%-25%), tubal factors (14%-20%), and other factors (cervical, peritoneal or uterine factors or abnormalities) (10%-13%).

- Ovulation disorders can be caused by polycystic ovary syndrome (PCOS), diminished ovarian reserve, functional hypothalamic amenorrhea, improper functioning of the hypothalamus and pituitary glands, premature ovarian insufficiency, and menopause. Of these, the most common is PCOS which accounts for 80% of infertility due to anovulation. Individuals with PCOS have normal or low follicle stimulating hormone (FSH) and mildly increased luteinizing hormone (LH).
- Fallopian tube obstruction or tubal occlusion can be caused by a history of pelvic infection, ruptured appendicitis, history of gonorrhea or chlamydia, endometriosis, or a history of abdominal surgery.
- Abnormal uterine contour or other anatomic abnormalities such as fibroids can also cause infertility.
- Other factors which decrease fertility include increasing age, smoking, excessive alcohol use, extreme weight gain or loss, and excessive stress. Functional hypothalamic amenorrhea (FHA) is defined as chronic anovulation without identifiable cause associated with stress, weight loss, and/or excessive exercise. Hypogonadotropic amenorrhea (HA) involves low or



absent gonadotropin releasing hormone (GnRH) secretion due to FHA, congenital or iatrogenic causes, or pituitary adenomas.

## Standards of Practice

The following outlines the steps in the process of ovulation induction.

- Initial ovulation induction typically occurs with oral agents such as clomiphene or letrozole.
- Clomiphene resistance or failure to ovulate on clomiphene occurs in approximately 20% of women. Of those who ovulate on clomiphene, 50% do not become pregnant within 6 months and are considered clomiphene failures. In both groups of individuals, second-line treatment may include gonadotropins or laparoscopic ovarian diathermy. During treatment, follicle growth is regularly monitored via serial transvaginal ultrasounds every 1-3 days and serum estradiol is assessed daily.
- If individuals are treated with gonadotropins, these drugs are administered for 7-12 days at the beginning of a cycle. Initially, low dose treatment is recommended (37.5-75 IU/d) to decrease risk of multiple pregnancy. This dose may be increased based on response to therapy. Combination FSH and LH products are recommended for individuals with hypogonadotropic amenorrhea such as human menopausal gonadotropin or low-dose human menopausal gonadotropin. In individuals with PCOS, only FSH is required. Of note, LH doesn't appear harmful and combination products such as human menopausal gonadotropin are often given in PCOS.
- In both hypogonadotropic amenorrhea and PCOS, human chorionic gonadotropin (hCG; 5,000-10,000 units purified hCG or 250 mcg recombinant) is administered after development of a mature follicle to stimulate ovum release. In PCOS, a GnRH agonist (leuprolide 500 mcg SC or triptorelin 200 mcg SC) with progesterone supplementation during the luteal phase is an alternative to hCG if a GnRH agonist was not given earlier to prevent LH surge. Additionally, progesterone supplementation with low-dose hCG every 3-4 days are recommended in individuals with hypogonadotropic amenorrhea to support normal luteal functions.

The American Society of Reproductive Medicine, European Society of Endocrinology and the Pediatric Endocrinology Society published guidelines on the diagnosis and treatment of FHA in 2018. The guidelines recommend first correcting any energy imbalance by increasing calorie consumption, improving nutrition, or decreasing exercise. If individuals wish to conceive, GnRH



is recommended first line; however, this is not available in the U.S. Gonadotropin therapy is recommended second-line for ovulation induction.

The following outlines a general overview of the ART process:

- Protocols for *in vitro* fertilization (IVF) typically involve suppression of gonadotropin release to prevent premature LH surges. This allows greater retrieval of oocytes and higher pregnancy rates. Both GnRH agonists and antagonists are used for this purpose in IVF protocols.
- Follicle growth is stimulated via gonadotropins as described above.
- This is followed by hCG or GnRH agonists that trigger the final maturation of oocytes in preparation for retrieval and fertilization. GnRH agonists can only be used for this purpose if GnRH antagonists at standard doses were used to suppress gonadotropin release and prevent premature LH surges.
- Eggs are collected typically using transvaginal ultrasound as a guide.
- Fertilization occurs either via IVF or intracytoplasmic sperm injection. This is followed by laboratory procedures for embryo culture.
- Embryos are placed in the uterus followed by luteal phase support such as progesterone, estrogen, or hCG.

## Summary of Evidence

### Meaningful Differences in Efficacy in Clinical Trials

Specialty fertility drugs are used in the process of ovulation induction as well as in the setting of assisted reproductive technology such as IVF or intracytoplasmic sperm injection. A total of four guidelines and six meta-analyses pertaining to the efficacy of specialty fertility drugs were identified. In the setting of infertility due to PCOS, the American Society of Reproductive Medicine and the World Health Organization guidelines recommend gonadotropins as second-line treatment for ovulation induction following non-specialty first-line agents such as clomiphene and letrozole. Both guidelines recommend IVF as third-line treatment in this setting.

All guidelines and meta-analyses found no difference or insufficient evidence of a difference in the primary efficacy measures of live birth rate or pregnancy between gonadotropins in the setting of ovulation induction and IVF. Specifically, no difference was found between urinary or



recombinant FSH or between FSH products and hMG. The World Health Organization guidelines recommend that the choice of gonadotropin is based on cost of therapy as no difference in effectiveness has been identified. A total of two meta-analyses assessed GnRH antagonist and agonist protocols in IVF both found no differences in the live birth rate. Finally, a single meta-analysis compared GnRH agonists and hCG for oocyte triggering found no difference in the live birth rate.

## Differences in Safety Profiles

Ovarian hyperstimulation syndrome (OHSS) is a potentially life-threatening complication of fertility drugs and consists of an increase in vascular permeability resulting in a rapid accumulation of fluid in the peritoneal cavity, thorax, and pericardium. The American Society of Reproductive Medicine and World Health Organization guidelines as well as three meta-analyses found decreased risk of OHSS with GnRH antagonists compared to GnRH agonists. Therefore, both guidelines recommend the use of GnRH antagonists protocols in IVF. Additionally, a meta-analysis found the risk of OHSS was decreased with GnRH agonists compared to hCG in the setting oocyte triggering.

The risk of cancer following fertility treatment has been assessed in a guideline and meta-analysis, both limited by low-quality study data. The American Society of Reproductive Medicine guideline found a small increase in absolute risk of borderline ovarian tumors following fertility treatment; however, there was insufficient evidence of increased risk with any particular fertility drug. There was no evidence of increased cancer risk with any other cancer type. The meta-analysis found inconclusive evidence of endometrial cancer risk with gonadotropins; no other specialty drugs were evaluated. Lastly, a meta-analysis found no increased risk of cardiovascular (CV) outcome with exposure to fertility drugs.

## 2021 Update

Reviewed prescribing information for all drugs listed in policy and market availability for products. No new evidence was identified that would change coverage criteria. Changed policy title from Pharmacologic Treatment of Infertility to Pharmacologic Treatment in Assisted Reproduction to further align with the member benefit booklet and contract language. Updated policy criteria for all drugs from “treatment of infertility” to “use in assisted reproduction” to sync with policy title change.



## 2022 Update

Reviewed prescribing information for all drugs listed in policy. No new evidence was identified that would change coverage criteria.

## 2023 Update

Reviewed prescribing information for all drugs listed in policy. Bravelle (urofollitropin) was removed from the policy as it has been discontinued.

## References

1. Pregnyl® (chorionic gonadotropin for injection) prescribing information. Merck & Co., Inc.; Whitehouse Station, NJ. Revised January 2015.
2. Novarel® (chorionic gonadotropin for injection) prescribing information. Ferring Pharmaceuticals Inc.; Parsippany, NJ. Revised May 2018.
3. Ovidrel® (choriogonadotropin alfa injection) prescribing information. EMD Serono, Inc.; Rockland, MD. Revised June 2018.
4. Follistim® AQ Cartridge (follitropin beta injection) prescribing information. Merck & Co., Inc.; Whitehouse Station, NJ. Revised June 2020.
5. Gonal-f® (follitropin alfa for injection) prescribing information. EMD Serono, Inc.; Rockland, MD. Revised December 2020.
6. Gonal-f® RFF (follitropin alfa for injection) prescribing information. EMD Serono, Inc.; Rockland, MD. Revised December 2020.
7. Gonal-f® RFF Redi-ject® (follitropin alfa for injection) prescribing information. EMD Serono, Inc.; Rock-land, MD. February 2020.
8. Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Fertil Steril*. 2018;110(3):364-379.
9. Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. *Hum Reprod Update*. 2016;22(6):687-708.
10. Weiss NS, Kostova E, Nahuis M, Mol BWJ, van der Veen F, van Wely M. Gonadotrophins for ovulation induction in women with polycystic ovary syndrome. *Cochrane Database of Systematic Reviews* 2019, Issue 1. Art. No.: CD010290. DOI: 10.1002/14651858.CD010290.pub3.
11. Farquhar C, Majorlbanks J. Assisted reproductive technology: an overview of Cochrane Reviews. *Cochrane Database of Systematic Reviews* 2018, Issue 8. Art. No.: CD010537. DOI: 10.1002/14651858.CD010537.pub5.
12. Kollmann M, Martins WP, Lima MS, et al. Strategies for improving outcome of assisted reproduction in women with polycystic ovary syndrome: systematic review and meta-analysis. *Ultrasound Obstet Gynecol*. 2016;48:709-718.





13. Wang R, Lin S, Wag Y, Qian W, Zhou L. Comparisons of GnRH antagonist protocols versus GnRH agonist long protocol in patients with normal ovarian reserve; a systematic review and meta-analysis. PLoS ONE. 2017a;12(4):e0175985.
14. Youssef MA, van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database of Systematic Reviews 2014, Issue 10. Art. No.: CD00 8046. DOI: 10.1002/14651858.CD008046.pub4.
15. Skalkidou A, Serghianis TN, Gialamas SP, et al. Risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertility. Cochrane Database of Systematic Reviews 2017, Issue 3. Art. No.: CD010931. DOI: 10.1002/14651858.CD010931.pub2.
16. Practice Committee of the American Society for Reproductive Medicine. Fertility drugs and cancer: a guideline. Fertil Steril. 2016;106 (7):1617-1626.
17. Dayan N, Filion KB, Okano M, et al. Cardiovascular risk following fertility therapy: systematic review and meta-analysis. J Am Coll Cardiol. 2017;70(10):1203-1213.
18. Wang R, Kim BV, van Wely M, et al. Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis. BMJ. 2017b;356:j138.
19. Lindsay TJ, Vitrikas KR. Evaluation and treatment of infertility. Am Fam Physician. 2015;91(5):308-314.
20. Practice Committee of the American Society for Reproductive Medicine. Use of exogenous gonadotropins in anovulatory women: a technical bulletin. Fertil Steril. 2008a;90 (Suppl 3):S7-S12.
21. Gordon CM, Ackerman KE, Berga SL, et al. Functional hypothalamic amenorrhea: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(5):1413-1439.
22. Practice Committee of the American Society for Reproductive Medicine. Comparison of pregnancy rates with poor responders using IV with mild ovarian stimulation versus conventional IVF: a guideline. Fertil Steril. 2018;109(6):993-999.

## History

Date	Comments
07/01/20	New policy, approved June 25, 2020, effective October 2, 2020, following 90-day provider notification. Add to Prescription Drug section. Bravelle (urofollitropin), brand Chorionic Gonadotropin, Follistim AQ, and Pregnyl (chorionic gonadotropin) may be considered medically necessary for the treatment of infertility when criteria are met. Coverage criteria for Bravelle (urofollitropin), brand Chorionic Gonadotropin, Follistim AQ, and Pregnyl (chorionic gonadotropin) becomes effective for dates of service on or after October 2, 2020.
02/01/21	Interim Review, approved January 21, 2021. Added Follistim AQ (follitropin beta) to require coverage review under the Medical Benefit. Added HCPC code S0128 for Follistim.
01/01/22	Annual Review, approved December 2, 2021. Changed policy title from Pharmacologic Treatment of Infertility to Pharmacologic Treatment in Assisted Reproduction. Updated policy criteria for all drugs from "treatment of infertility" to "use in assisted reproduction".



Date	Comments
01/01/23	Annual Review, approved December 23, 2022. No changes to policy statements. Changed the wording from "patient" to "individual" throughout the policy for standardization.
12/01/23	Annual Review, approved November 20, 2023. Bravelle (urofollitropin) was removed from the policy as it has been discontinued. Removed HCPCS code J3355 as Bravelle (urofollitropin) has been discontinued.

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2023 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.



## Discrimination is Against the Law

Premera Blue Cross (Premera) complies with applicable Federal and Washington state civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. Premera provides free aids and services to people with disabilities to communicate effectively with us, such as qualified sign language interpreters and written information in other formats (large print, audio, accessible electronic formats, other formats). Premera provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, contact the Civil Rights Coordinator. If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation, you can file a grievance with: Civil Rights Coordinator — Complaints and Appeals, PO Box 91102, Seattle, WA 98111, Toll free: 855-332-4535, Fax: 425-918-5592, TTY: 711, Email [AppealsDepartmentInquiries@Premera.com](mailto:AppealsDepartmentInquiries@Premera.com). You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Ave SW, Room 509F, HHH Building, Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD). Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

**Washington residents:** You can also file a civil rights complaint with the Washington State Office of the Insurance Commissioner, electronically through the Office of the Insurance Commissioner Complaint Portal available at <https://www.insurance.wa.gov/file-complaint-or-check-your-complaint-status>, or by phone at 800-562-6900, 360-586-0241 (TDD). Complaint forms are available at <https://fortress.wa.gov/oic/online-services/cc/pub/complaintinformation.aspx>.

**Alaska residents:** Contact the Alaska Division of Insurance via email at [insurance@alaska.gov](mailto:insurance@alaska.gov), or by phone at 907-269-7900 or 1-800-INSURAK (in-state, outside Anchorage).

## Language Assistance

**ATENCIÓN:** si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 800-722-1471 (TTY: 711).

**PAUNAWA:** Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 800-722-1471 (TTY: 711).

**注意:** 如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 800-722-1471 (TTY: 711)。

**CHÚ Ý:** Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 800-722-1471 (TTY: 711).

**주의:** 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 800-722-1471 (TTY: 711) 번으로 전화해 주십시오.

**ВНИМАНИЕ:** Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 800-722-1471 (телетайп: 711).

**LUS CEEV:** Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 800-722-1471 (TTY: 711).

**MO LOU SILAFIA:** Afai e te tautala Gagana fa'a Sāmoa, o loo iai auunaga fesoasoan, e fai fua e leai se totagi, mo oe, Telefoni mai: 800-722-1471 (TTY: 711).

**ໂປດອຸລາ:** ຖ້າວ່າ ທ່ານເວົ້າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ຄ່າສ່ຽງຄ່າ, ຄມມຸນມິພ້ອມໃຫ້ທ່ານ. ໂທ 800-722-1471 (TTY: 711).

**注意事項:** 日本語を話される場合、無料の言語支援をご利用いただけます。800-722-1471 (TTY:711) まで、お電話にてご連絡ください。

**PAKDAAR:** Nu saritaem ti Ilocano, ti serbisyo para ti baddang ti lengguahe nga awanan bayadna, ket sidadaan para kenyan. Awagan ti 800-722-1471 (TTY: 711).

**УВАГА!** Якщо ви розмовляєте українською мовою, ви можете звернутися до безкоштовної служби мовної підтримки. Телефонуйте за номером 800-722-1471 (телетайп: 711).

**ប្រយ័ត្ន:** បើសិនជាអ្នកនិយាយ ភាសាខ្មែរ, សេវាជំនួយផ្នែកភាសា ដោយមិនគិតលុយ គឺអាចមានសំរាប់អ្នក។ ចូរ ទូរស័ព្ទ 800-722-1471 (TTY: 711)។

**ማስታወሻ:** የሚናገሩት ቋንቋ አማርኛ ከሆነ የትርጉም አርዳታ ድርጅቶች: በነጻ ሊያግኙዎት ተዘጋጅተዋል: ወደ ሚከተለው ቁጥር ይደውሉ 800-722-1471 (መስማት ለተሳናቸው: 711).

**XIYYEEFFANNAA:** Afaan dubbattu Oroomiffa, tajaajjila gargaarsa afaanii, kanfaltiidhaan ala, ni argama. Bilbilaa 800-722-1471 (TTY: 711).

**ملحوظة:** إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 800-722-1471 (رقم هاتف الصم والبكم: 711).

**ਧਿਆਨ ਦਿਓ:** ਜੇ ਤੁਸੀਂ ਪੰਜਾਬੀ ਬੋਲਦੇ ਹੋ, ਤਾਂ ਭਾਸ਼ਾ ਵਿੱਚ ਸਹਾਇਤਾ ਸੇਵਾ ਤੁਹਾਡੇ ਲਈ ਮੁਫਤ ਉਪਲਬਧ ਹੈ। 800-722-1471 (TTY: 711) 'ਤੇ ਕਾਲ ਕਰੋ।

**ထိစား:** ถ้าคุณพูดภาษาไทยคุณสามารถใช้บริการช่วยเหลือทางภาษาได้ฟรี โทร 800-722-1471 (TTY: 711).

**ACHTUNG:** Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 800-722-1471 (TTY: 711).

**UWAGA:** Jeżeli mówisz po polsku, możesz skorzystać z bezpłatnej pomocy językowej. Zadzwoń pod numer 800-722-1471 (TTY: 711).

**ATANSYON:** Si w pale Kreyòl Ayisyen, gen sèvis èd pou lang ki disponib gratis pou ou. Rele 800-722-1471 (TTY: 711).

**ATTENTION:** Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 800-722-1471 (ATS: 711).

**ATENÇÃO:** Se fala português, encontram-se disponíveis serviços linguísticos, grátis. Ligue para 800-722-1471 (TTY: 711).

**ATTENZIONE:** In caso la lingua parlata sia l'italiano, sono disponibili servizi di assistenza linguistica gratuiti. Chiamare il numero 800-722-1471 (TTY: 711).

**توجه:** اگر بہ زبان فارسی گفتگو می کنید، تسهیلات زبانی بصورت رایگان برای شما فراهم می باشد. با 800-722-1471 (TTY: 711) تماس بگیرید.